Figure 2From: Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype Effects of dasatinib on c-Src phosphorylation in MDA-MB-157 cells. Dasatinib dose-dependently decreased the expression levels of p-Src (Y416 and Y-527) but not that of c-Src.Back to article page